Key result
First-generation bioresorbable scaffolds linked to higher thrombosis vs. DES, with excess risk ending at 3 years.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: The higher scaffold thrombosis rates observed with the first-generation bioresorbable scaffolds (BRSs) compared to conventional drug-eluting stents were likely due in part to bioresorbable polymers having insufficient radial strength, necessitating larger strut profiles. Meta-analysis of the long-term outcomes from the first-generation Absorb bioresorbable vascular scaffold (BVS) showed that this period of excess risk ended at 3 years. Therefore, current attention has been focused on improving early outcomes by increasing the scaffold's tensile strength and reducing strut thickness. AREAS COVERED: This review summaries the lessons learned from the first-generation BRS. It updates the long-term clinical outcomes of trials evaluating the ABSORB BVS and metallic alloy-based BRS. In addition, it reviews the next-generation BRSs manufactured in Asia. EXPERT OPINION: Critical areas to improve the performance and safety of biodegradable scaffolds include further development in material science, surface modification, delivery systems, and long-term follow-up studies.
No takes yet. Share an insight, caveat, or question.
Miyashita et al. (2024) reported a review. Bioresorbable vascular scaffolds vs. Conventional drug-eluting stents was evaluated. First-generation bioresorbable vascular scaffolds were associated with higher scaffold thrombosis rates compared to conventional drug-eluting stents, though this excess risk ended at 3 years.
Synapse has enriched 10 related papers. Consider them for comparative context: